<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20170221032698N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-09-20</date_registration>
      <primary_sponsor>Yazd University of Medical Sciences</primary_sponsor>
      <public_title>The effect of low calorie diets on anthropometric, glycemic, cardiovascular and hormonal factors in people with polycystic ovary syndrome</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the effect of Modified Alternate Day Fasting in comparison with energy restriction (Calorie Restriction) on anthropometric indices, glycemic markers, lipid parameters and hormone levels in people with polycystic ovary syndrome</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>44</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/58762</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: All participants were stratified for body mass index (BMI) and age, and were randomly assigned to ADF or CR group for 10 weeks. Randomization was performed using by random- generation software.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Polycystic ovary syndrome.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The normal diet of individuals is observed and followed for 2 weeks. Then, the ADF group consumed 25% of their energy on 3 days of the week (Saturday, Monday, Wednesday) for 8 weeks and then ate diet that providing 125% of their energy needs on each feed day (3 days a week). In Friday subjects consume ad libitum without limitation. These people received between 400 and 600 kcal of energy on fasting days. The feed and fast days began at midnight each day, and all fast day meals were consumed between 12.00 pm and 2.00 pm to ensure that each subject was undergoing the same duration of fasting. all food prepared in the home. Subjects were permitted to consume calorie- free foods (such as water, green tea, coffee without sugar ( &lt; 400 mg caffeine per day), non- starchy vegetable (such as lettuce, cucumber, green leaf, tomato) and sugar free gums on the fast day and were encouraged to drink plenty of water. Intervention 2: Control group: The normal diet of individuals is observed and followed for 2 weeks. Then, in Calorie Restriction group, subjects consumed 75% energy needs in each day for 8 weeks and includes 3 main meals and 2 snacks. All subjects in two groups were required to prepare all of their meals at home. The baseline energy requirements for the subjects were assessed by Mifflin equation. Daily dietary carbohydrate, fat and protein accounted for 52, 30 and 18% of ingested energy, respectively.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Reyhaneh azizi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Diabetes Research and Treatment Center, Shahid Sadoughi Ave., Yazd, Iran</address>
        <city>Yazd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8917693571</zip>
        <telephone>+98 35 3728 0226</telephone>
        <email>forough.nutritionist@gmail.com</email>
        <affiliation>Yazd University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Reyhaneh Azizi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Diabetes Research and Treatment Center, Shahid Sadoughi Ave., Yazd, Iran</address>
        <city>Yazd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8917693571</zip>
        <telephone>+98 35 3728 0226</telephone>
        <email>forough.nutritionist@gmail.com</email>
        <affiliation>Yazd University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Women with polycystic ovary syndrome
Age 25- 45 years
25 ≤ BMI  ≤ 40 kg/m2
Body weight more than 5 kg has not changed during the last 3 months
No fasting for 3 months prior to the beginning of the study
Absence of diseases such as diabetes, cardiovascular, kidney, thyroid disorders, liver diseases, etc.
Do not take medication, including drug that lower blood sugar, blood pressure and lipids. Also drugs that affect glycemic index and lipid parameters.
No smoking and alcohol
Intense physical inactivity
Failure to follow specific diets
People who, after explaining the work, are willing to cooperate and answer questions and perform experiments.</inclusion_criteria>
      <agemin>25 years</agemin>
      <agemax>45 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Lack of cooperation of participants in different stages of project implementation
People who lose the conditions to enter the study</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E28.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Polycystic ovarian syndrome</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Lifestyle</i_code>
      <i_code>Lifestyle</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The normal diet of individuals is observed and followed for 2 weeks. Then, the ADF group consumed 25% of their energy on 3 days of the week (Saturday, Monday, Wednesday) for 8 weeks and then ate diet that providing 125% of their energy needs on each feed day (3 days a week). In Friday subjects consume ad libitum without limitation. These people received between 400 and 600 kcal of energy on fasting days. The feed and fast days began at midnight each day, and all fast day meals were consumed between 12.00 pm and 2.00 pm to ensure that each subject was undergoing the same duration of fasting. all food prepared in the home. Subjects were permitted to consume calorie- free foods (such as water, green tea, coffee without sugar ( &lt; 400 mg caffeine per day), non- starchy vegetable (such as lettuce, cucumber, green leaf, tomato) and sugar free gums on the fast day and were encouraged to drink plenty of water.</i_keyword>
      <i_keyword>Control group: The normal diet of individuals is observed and followed for 2 weeks. Then, in Calorie Restriction group, subjects consumed 75% energy needs in each day for 8 weeks and includes 3 main meals and 2 snacks. All subjects in two groups were required to prepare all of their meals at home. The baseline energy requirements for the subjects were assessed by Mifflin equation. Daily dietary carbohydrate, fat and protein accounted for 52, 30 and 18% of ingested energy, respectively.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Body Weighy. Timepoint: Two times, before and after dietary intervention. Method of measurement: Weight with minimal coverage and without shoes using a SECA weight scale with an accuracy of 100 grams.</prim_outcome>
      <prim_outcome>BMI. Timepoint: Two times, before and after dietary intervention. Method of measurement: Divide weight (kg) by height squared (m2).</prim_outcome>
      <prim_outcome>Waist circumference. Timepoint: Two times, before and after dietary intervention. Method of measurement: Between the lower margin of the last rib and the crown of the iliac bone at the level of the umbilicus and at the end of natural exhalation from the garment.</prim_outcome>
      <prim_outcome>Blood pressure. Timepoint: Two times, before and after dietary intervention. Method of measurement: Blood pressure is measured using a mercury sphygmomanometer after sitting for 10 minutes.</prim_outcome>
      <prim_outcome>Fasting blood sugar. Timepoint: Two times, before and after dietary intervention. Method of measurement: In the FBS test, the patient should fast for 10-12 hours. Its normal amount varies according to the kit and test method. In the enzymatic method, FBS in normal adults is 110-70 mg / dl.</prim_outcome>
      <prim_outcome>Total cholesterol. Timepoint: Two times, before and after dietary intervention. Method of measurement: The amount (TC) is measured by enzymatic methods.</prim_outcome>
      <prim_outcome>HDL. Timepoint: Two times, before and after dietary intervention. Method of measurement: The amount (HDL) is measured by enzymatic methods.</prim_outcome>
      <prim_outcome>Triglyceride. Timepoint: Two times, before and after dietary intervention. Method of measurement: The amount (TG) is measured by enzymatic methods.</prim_outcome>
      <prim_outcome>LDL. Timepoint: Two times, before and after dietary intervention. Method of measurement: Serum LDL will also be calculated using the Friedwald equation.</prim_outcome>
      <prim_outcome>Fat Mass. Timepoint: Two times, before and after dietary intervention. Method of measurement: Body composition analyzer.</prim_outcome>
      <prim_outcome>Fat Free Mass. Timepoint: Two times, before and after dietary intervention. Method of measurement: Body composition analyzer.</prim_outcome>
      <prim_outcome>Fasting insulin. Timepoint: Two times, before and after dietary intervention. Method of measurement: fasting insulin was assayed using ELISA kits.</prim_outcome>
      <prim_outcome>HOMA- IR. Timepoint: Two times, before and after dietary intervention. Method of measurement: HOMA-IR = fasting insulin (μU/ml) × fasting blood sugar (mg/dl) / 405.</prim_outcome>
      <prim_outcome>FSH. Timepoint: Two times, before and after dietary intervention. Method of measurement: FSH levels will be measured through the ELISA kit.</prim_outcome>
      <prim_outcome>LH. Timepoint: Two times, before and after dietary intervention. Method of measurement: LH levels will be measured through the ELISA kit.</prim_outcome>
      <prim_outcome>TSH. Timepoint: Two times, before and after dietary intervention. Method of measurement: TSH levels will be measured through the ELISA kit.</prim_outcome>
      <prim_outcome>Testosterone. Timepoint: Two times, before and after dietary intervention. Method of measurement: testosterone levels will be measured through the ELISA kit.</prim_outcome>
      <prim_outcome>Prolactin. Timepoint: Two times, before and after dietary intervention. Method of measurement: ICMA will be used to measure serum prolactin levels.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Yazd University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-06-30</approval_date>
        <contact_name>Ethics committe of Shahid Sadoughi University of Medical Sciences</contact_name>
        <contact_address>Bahonar Sq., Shahid Sadoughi Ave., Shahid Sadoughi University of Medical Sciences, Yazd Yazd Yazd Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
